Skip to main content
TeamingIndex
Unclaimed profileSeeded from SAM.gov and USAspending public records
Claim this profileCapability statement (.md)

INHALON BIOPHARMA, INC.

  • MORRISVILLE, NC 27560-8425
  • Corporate Entity (Not Tax Exempt)
UEIHFQSJ2GMNRU6CAGE87U21NAICS541714
  • SAM active
  • No verified credentials yet
  • CMMCNot on file
  • SPRSNone
  • FCLVisible to paid members
  • Small Business

Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works

36-mo obligations
$5.4M
Awards on record
2
Contract vehicles
0
Verified credentials
0

Compliance posture: unverified (SAM.gov baseline only)

INHALON BIOPHARMA, INC. has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0

Claim this profile

About INHALON BIOPHARMA, INC.

INHALON BIOPHARMA, INC. is a SAM.gov-registered entity based in MORRISVILLE, NC 27560-8425. UEI HFQSJ2GMNRU6; CAGE 87U21; primary NAICS 541714. Compliance posture not provided. Active SAM registration.
Headquarters
MORRISVILLE, NC 27560-8425

Identifiers

UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.

  • UEIHFQSJ2GMNRU6
  • CAGE87U21

Capabilities & differentiators

No capability narrative yet

The company has not published a capability narrative. Its SAM.gov registration, NAICS codes and award history are below.
Is this your company? Claim it

Compliance posture

Every credential shows who vouches for it: verified by TeamingIndex, or self-attested by the contractor.

No compliance posture published yet

Compliance facts appear once the company claims this profile and publishes them.
Is this your company? Claim it

Facility clearance

Facility clearance: visible to paid members

Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans

Past performance

Recompete RadarLearn more about past performance
Prime awards from USAspending.gov (FPDS), synced nightly. Recompete windows use the potential end date (base plus all options).
36-month obligations
$5.4M
Awards on record
2
Top funding agencies
Defense Health Agency

Awards

Contract vehicles

Learn more about GWACs, IDIQs and contract vehicles

No contract vehicles on file

This company has not listed GWAC, IDIQ, GSA Schedule or OTA consortium holdings.
Browse vehicle holders

Proven teaming graph

Learn more about sub-award reporting (FSRS)
Who INHALON BIOPHARMA, INC. has actually worked with, from sub-awards that prime contractors report to the government. Use it to see which primes already trust this company.

No sub-award reports yet

Prime contractors report first-tier subcontracts of $30,000 or more. None name this company yet, which is common for companies that mostly win prime contracts or work below the reporting threshold.
See where agencies spend

Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.

SBIR/STTR portfolio

Learn more about SBIR/STTR Phase IIIAbout SBIR/STTR (opens in a new tab)
Small Business Innovation Research and Technology Transfer awards: early-stage federal R&D money this company has won.

SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects

Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.

Awards on record
7 awards
Total awarded
$12,822,673
By phase
  • SBIR Phase II: 7
By agency
  • Department of Health and Human Services: 7
Active projects
4 projects
Projects whose contract end date is today or later.
Phase II ending within 12 months
2 projects
Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
By year
  • 2025: 2
  • 2024: 3
  • 2023: 1
  • 2022: 1

Awards (most recent first)

  • Development of IN-003PI as passive immunization against human metapneumovirus infection

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2025 · $1,013,468

    Sep 1, 2025 – Jul 31, 2028

    • Active

    Solicitation PA24-245 (2024) · Topic NIAID

  • IND-enabling development for IN-005, an inhaled muco-trapping mAb therapy against Influenza A

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2025 · $1,013,003

    Aug 1, 2025 – Jul 31, 2028

    • Active

    Solicitation PA24-245 (2024) · Topic N

  • Pharmacokinetics analysis from first-in-human study of IN-002, a potent inhaled muco-trapping antibody therapy for RSV

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $2,049,871

    Jun 21, 2024 – May 31, 2026

    Solicitation PA23-230 (2023) · Topic NIAID

  • IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infection

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $2,049,821

    May 15, 2024 – Apr 30, 2027

    • Active
    • Ends Apr 2027

    Solicitation PA23-230 (2023) · Topic NIAID

  • SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $2,048,861

    Mar 1, 2024 – Feb 28, 2027

    • Active
    • Ends Feb 2027

    Solicitation PA22-176 (2022) · Topic NIAID

  • GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $2,605,456

    Jun 1, 2023 – May 31, 2026

    Solicitation PAR20-129 (2020) · Topic NIAID

  • IND-enabling development for IN-002, an inhaled muco-trapping mAb against respiratory syncytial virus

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2022 · $2,042,193

    Jul 12, 2022 – Jun 30, 2024

    • Direct to Phase II

    Solicitation PA20-260 (2020) · Topic NIAID

Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026

FedRAMP offerings

Learn more about the FedRAMP Marketplace
Cloud services this company lists on the FedRAMP Marketplace, the government's record of cloud authorizations.

No FedRAMP Marketplace listing

No FedRAMP Marketplace listing is linked to this company. Cloud providers appear here automatically once FedRAMP lists their offering.
Find FedRAMP-authorized companies

Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded

Exclusions & screening

Exclusions about SAM.gov exclusionsScreening list about the Consolidated Screening List
Checks a prime runs before teaming: SAM.gov exclusions (debarment and suspension) and the government's Consolidated Screening List for export and sanctions lists.

SAM.gov exclusions

Not yet checked against SAM.gov exclusions.

Search exclusions on SAM.gov (opens in a new tab)

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded

Consolidated Screening List

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.

Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026

GSA CALC+ rate benchmark

Learn more about GSA CALC+ labor rates
Hourly ceiling rates this company was awarded on GSA contracts, compared with the market for similar labor categories. Ceiling rates are the most an agency can be charged, not prices paid.

No GSA CALC+ rates on record

Companies with a GSA Multiple Award Schedule contract appear here after CALC+ publishes their awarded labor rates.
See GSA MAS holders

Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded

NAICS, PSC & socio-economic status

Learn more about NAICS size standards
Industry codes and small-business programs reported in SAM.gov.

NAICS codes

  • 541714Research and Development in Biotechnology (except Nanobiotechnology)PrimarySmall business under this code’s size standard
  • 541380Testing Laboratories and ServicesSmall business under this code’s size standard
  • 541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

SAM.gov reports this entity as small under 2 of 3 NAICS codes. Size is determined per code (SBA size standards).

Socio-economic status

Learn more about small business set-asides

Product & service codes (PSC)

No PSC codes reported.

Teaming preferences

Learn more about teaming agreements and joint ventures

This company has not published teaming preferences.

SAM.gov teaming eligibility: Eligible to be proposed as a team member: active SAM.gov registration and no exclusion.

Business development contact

No BD contact published

Contact details appear once the company claims this profile.
Is this your company? Claim it

Corporate hierarchy

Affiliation & size about affiliation and size
Immediate parent and highest-level owner as reported in SAM.gov.

No parent entity reported in SAM.gov.

SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.

Data sources & provenance

Who stands behind each fact on this page, and how to correct it.

  • SAM.gov

    Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.

  • USAspending.gov

    Prime award history and obligations (FPDS), synced nightly.

  • The contractor

    Nothing yet: this profile has not been claimed by the company.

  • TeamingIndex verification

    Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.

Corrections

Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)

Machine-readable: capability.md schema.org JSON-LD embedded in this page.

Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.

Teaming

Ready to team with INHALON BIOPHARMA, INC.?

Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.

Claim this profileCapability statement (.md)